Baluna R, Ghetie V, Oppenheimer-Marks N, Vitetta E S
Department of Microbiology, University of Texas Southwestern Medical Center at Dallas 75235-8576, USA.
Int J Immunopharmacol. 1996 Jun-Jul;18(6-7):355-61. doi: 10.1016/s0192-0561(96)00043-4.
We have previously reported that after in vitro treatment with deglycosylated ricin A chain (dgRTA), human umbilical vein endothelial cells (HUVECs) undergo changes in morphology including cell rounding and disruption of monolayers. The present studies were carried out to determine whether these changes were related to the disruptions in endothelial cell (EC) interactions with the extracellular matrix. To this end, we examined the effect of dgRTA on HUVECs in the presence of fibronectin (Fn), an extracellular matrix protein, which plays a role in the maintenance of vascular integrity. The addition of exogenous Fn greatly inhibited dgRTA-mediated morphological changes in HUVEC monolayers, dgRTA-mediated inhibition of [3H]thymidine incorporation in HUVECs and the binding of 125I-dgRTA to HUVECs. Should the same phenomenon occur with RTA-based immunotoxins (ITs) in vivo, this might shed light on the development of dgRTA-mediated vascular leak syndrome (VLS) during IT therapy and provide new insights into how to decrease this toxicity in patients.
我们之前报道过,用人源化脱糖基化蓖麻毒素A链(dgRTA)进行体外处理后,人脐静脉内皮细胞(HUVECs)会发生形态变化,包括细胞变圆和单层细胞的破坏。本研究旨在确定这些变化是否与内皮细胞(EC)与细胞外基质相互作用的破坏有关。为此,我们在纤连蛋白(Fn)存在的情况下研究了dgRTA对HUVECs的影响,纤连蛋白是一种细胞外基质蛋白,在维持血管完整性方面发挥作用。添加外源性Fn可极大地抑制dgRTA介导的HUVEC单层细胞形态变化、dgRTA介导的HUVECs中[3H]胸腺嘧啶核苷掺入的抑制以及125I-dgRTA与HUVECs的结合。如果基于RTA的免疫毒素(ITs)在体内出现相同现象,这可能会为IT治疗期间dgRTA介导的血管渗漏综合征(VLS)的发展提供线索,并为如何降低患者的这种毒性提供新的见解。